Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCAR-BCDR cells
- Development stage
- Phase 1
- Lead developer
- Legend Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
LCAR-BCDR cells are a universal CAR-T cell therapy developed to target B-cell maturation antigen (BCMA), a protein specifically expressed on mature B lymphocytes and plasma cells. Upon administration, these engineered T cells recognize and kill tumor cells expressing BCMA through immunologic cytotoxicity. The primary indication for LCAR-BCDR is the treatment of relapsed or refractory multiple myeloma. The product is being developed by Nanjing Legend Biotech and is currently in Phase 1 clinical trials[1][2]. As a CAR-T cell therapy, it represents an advanced form of adoptive cell transfer designed to harness the patient’s immune system against hematologic malignancies.
- Other names
- CAR-T Re-treatmentBCMA-targeted CAR-T cell re-treatment
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on LCAR-BCDR cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCAR-BCDR cells.